Human Exosome Component 9 Antibody

Catalog #: MAB11616 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB11616-100
MAB11616-SP

Select the "Bulk Orders" button to request additional sizes or formulations.

Detection of Exosome Component 9 in Human Colon Cancer.

2 Images

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Exosome Component 9 Antibody Summary

Species Reactivity

Human

Specificity

Detects a synthetic peptide specific for hEXOSC9 around amino acid 300 in Direct ELISA.

Source

Monoclonal Mouse IgG₁ Clone # 1090209

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Synthetic Peptide
Accession # Q06265

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Immunohistochemistry

3-25 µg/mL

Immersion fixed paraffin-embedded sections of human colon cancer

Immunocytochemistry

3-25 µg/mL

Immersion fixed U251-MG human malignant glioblastoma cell line

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry

View Larger

Detection of Exosome Component 9 in Human Colon Cancer. Exosome Component 9 was detected in immersion fixed paraffin-embedded sections of human colon cancer using Mouse Anti-Human Exosome Component 9 Monoclonal Antibody (Catalog # MAB11616) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nucleus. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Immunocytochemistry

View Larger

Detection of Exosome Component 9 in U251‑MG Human Cell Line. Exosome Component 9 was detected in immersion fixed U251‑MG human malignant glioblastoma cell line using Mouse Anti-Human Exosome Component 9 Monoclonal Antibody (Catalog # MAB11616) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the nucleus. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Exosome Component 9

Exosome Component 9 (EXOSC9) is a 49 kDa protein and one of the six core proteins of the RNA exosome complex. It is known that EXOSC9 is necessary for the normal differentiation of epidermal tissues. EXOSC9 is also necessary for P-body formation, stress resistance and tumorigenicity in cancers. Depletion of EXOSC9 attenuates stress resistance and P-body formation in cancer cells and higher EXOSC9 activity correlates with poor prognosis in some types of cancers.

References

Yoshino S, Matsui Y, Fukui Y, Seki M, Yamaguchi K, Kanamori A, Saitoh Y, Shimamura T, Suzuki Y, Furukawa Y, Kaneko S, Seiki M, Murakami Y, Inoue JI, Sakamoto T. EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells. Sci Rep. 2020 Jun 9;10(1):9275. doi: 10.1038/s41598-020-66455-2. PMID: 32518284; PMCID: PMC7283315.
Quttina M, Waiters KD, Khan AF, Karami S, Peidl AS, Babajide MF, Pennington J, Merchant FA, Bawa-Khalfe T. Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer. Cells. 2023 Oct 20;12(20):2495. doi: 10.3390/cells12202495. PMID: 37887339; PMCID: PMC10605189.

Entrez Gene IDs

5393 (Human); 50911 (Mouse); 294975 (Rat)

Alternate Names

Autoantigen PM/Scl 1; EC 3.1.13; exosome complex component RRP45; exosome complex exonuclease RRP45; Exosome Component 9; p5; p6; P75 polymyositis-scleroderma overlap syndrome associated autoantigen; PCH1D; PM/Scl-75; PMSCL autoantigen, 75kD; PMSCL1; polymyositis/scleroderma autoantigen 1 (75kD); Polymyositis/scleroderma autoantigen 1; polymyositis/scleroderma autoantigen 1, 75kDa; RRP45; Rrp45p